BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139:1115-1127. [PMID: 20727892 DOI: 10.1053/j.gastro.2010.08.023] [Cited by in Crossref: 137] [Cited by in F6Publishing: 119] [Article Influence: 11.4] [Reference Citation Analysis]
Number Citing Articles
1 Konda VJ, Waxman I. Endotherapy for Barrett's esophagus. Am J Gastroenterol. 2012;107:827-833. [PMID: 22488078 DOI: 10.1038/ajg.2012.70] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
2 Trifan A, Stanciu C, Girleanu I, Stoica OC, Singeap AM, Maxim R, Chiriac SA, Ciobica A, Boiculese L. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. World J Gastroenterol 2017; 23(35): 6500-6515 [PMID: 29085200 DOI: 10.3748/wjg.v23.i35.6500] [Cited by in CrossRef: 102] [Cited by in F6Publishing: 84] [Article Influence: 20.4] [Reference Citation Analysis]
3 Li J, Chen XL, Shaker A, Oshima T, Shan J, Miwa H, Feng C, Zhang J. Contribution of immunomodulators to gastroesophageal reflux disease and its complications: stromal cells, interleukin 4, and adiponectin. Ann N Y Acad Sci 2016;1380:183-94. [PMID: 27441783 DOI: 10.1111/nyas.13157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
4 Savarino V, Dulbecco P, Savarino E. Are proton pump inhibitors really so dangerous? Dig Liver Dis. 2016;48:851-859. [PMID: 27321544 DOI: 10.1016/j.dld.2016.05.018] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
5 Bischoff LM, Faraco LSM, Machado LV, Bialecki AVS, Almeida GM, Becker SCC. INAPPROPRIATE USAGE OF INTRAVENOUS PROTON PUMP INHIBITORS AND ASSOCIATED FACTORS IN A HIGH COMPLEXITY HOSPITAL IN BRAZIL. Arq Gastroenterol 2021;58:32-8. [PMID: 33909794 DOI: 10.1590/S0004-2803.202100000-07] [Reference Citation Analysis]
6 Metz DC. Commentary: netazepide for gastric acid suppression - another kid on the block? Aliment Pharmacol Ther 2012;36:294-5. [DOI: 10.1111/j.1365-2036.2012.05183.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Linsky A, Hermos JA, Lawler EV, Rudolph JL. Proton pump inhibitor discontinuation in long-term care. J Am Geriatr Soc. 2011;59:1658-1664. [PMID: 21883102 DOI: 10.1111/j.1532-5415.2011.03545.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
8 Tick H, Nielsen A, Pelletier KR, Bonakdar R, Simmons S, Glick R, Ratner E, Lemmon RL, Wayne P, Zador V; Pain Task Force of the Academic Consortium for Integrative Medicine and Health. Evidence-Based Nonpharmacologic Strategies for Comprehensive Pain Care: The Consortium Pain Task Force White Paper. Explore (NY) 2018;14:177-211. [PMID: 29735382 DOI: 10.1016/j.explore.2018.02.001] [Cited by in Crossref: 112] [Cited by in F6Publishing: 85] [Article Influence: 28.0] [Reference Citation Analysis]
9 Park JH, Song YM, Jung JH, Han K. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study. Bone 2020;135:115306. [PMID: 32126312 DOI: 10.1016/j.bone.2020.115306] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, Sauvanet A, Kianmanesh R;  Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95:98-119. [PMID: 22261919 DOI: 10.1159/000335591] [Cited by in Crossref: 332] [Cited by in F6Publishing: 248] [Article Influence: 33.2] [Reference Citation Analysis]
11 Lin KJ, Hernández-Díaz S, García Rodríguez LA. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology. 2011;141:71-79. [PMID: 21458456 DOI: 10.1053/j.gastro.2011.03.049] [Cited by in Crossref: 68] [Cited by in F6Publishing: 56] [Article Influence: 6.2] [Reference Citation Analysis]
12 Lin YC, Huang YT, Lee TF, Lee NY, Liao CH, Lin SY, Ko WC, Hsueh PR. Characteristics of patients with Clostridium difficile infection in Taiwan. Epidemiol Infect. 2013;141:2031-2038. [PMID: 23218131 DOI: 10.1017/s0950268812002749] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
13 Savarino E, Marabotto E, Zentilin P, Furnari M, Bodini G, Pellegatta G, Lorenzon G, Della Coletta M, Ghisa M, Coppo C, Marinelli C, Savarino V. A safety review of proton pump inhibitors to treat acid-related digestive diseases. Expert Opinion on Drug Safety 2018;17:785-94. [DOI: 10.1080/14740338.2018.1497155] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
14 Huang X, Sun X, Yu X, Qian H. WITHDRAWN: Efficacy and safety of Sijunzi decoction for peptic ulcers: a systematic review and meta-analysis. Journal of Traditional Chinese Medical Sciences 2018. [DOI: 10.1016/j.jtcms.2018.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Helgadottir H, Bjornsson ES. Problems Associated with Deprescribing of Proton Pump Inhibitors. Int J Mol Sci 2019;20:E5469. [PMID: 31684070 DOI: 10.3390/ijms20215469] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
16 Martín-Merino E, Johansson S, Bueno H, García Rodríguez LA. Discontinuation of low-dose acetylsalicylic acid therapy in UK primary care: incidence and predictors in patients with cardiovascular disease. Pragmat Obs Res 2012;3:1-9. [PMID: 27774013 DOI: 10.2147/POR.S29557] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
17 Hassall E. Over-prescription of acid-suppressing medications in infants: how it came about, why it's wrong, and what to do about it. J Pediatr 2012;160:193-8. [PMID: 22018908 DOI: 10.1016/j.jpeds.2011.08.067] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
18 Pinto-sanchez MI, Yuan Y, Bercik P, Moayyedi P, Pinto-sanchez MI. Proton pump inhibitors for functional dyspepsia. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd011194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Kuiper JG, Herk‐sukel MPP, Lemmens VEPP, Kuipers EJ, Herings RMC. Proton pump inhibitors are not associated with an increased risk of colorectal cancer. GastroHep 2020;2:165-70. [DOI: 10.1002/ygh2.409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Jena AB, Sun E, Goldman DP. Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. J Gen Intern Med 2013;28:223-30. [PMID: 22956446 DOI: 10.1007/s11606-012-2211-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
21 Mazer-Amirshahi M, Mullins PM, van den Anker J, Meltzer A, Pines JM. Rising rates of proton pump inhibitor prescribing in US emergency departments. Am J Emerg Med 2014;32:618-22. [PMID: 24721025 DOI: 10.1016/j.ajem.2014.03.019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
22 Paroni Sterbini F, Palladini A, Masucci L, Cannistraci CV, Pastorino R, Ianiro G, Bugli F, Martini C, Ricciardi W, Gasbarrini A, Sanguinetti M, Cammarota G, Posteraro B. Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients. Appl Environ Microbiol. 2016;82:6633-6644. [PMID: 27590821 DOI: 10.1128/aem.01437-16] [Cited by in Crossref: 42] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
23 Juillerat P, Schneeweiss S, Cook EF, Ananthakrishnan AN, Mogun H, Korzenik JR. Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36:239-247. [PMID: 22670722 DOI: 10.1111/j.1365-2036.2012.05173.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
24 Sáez ME, González-pérez A, Gaist D, Johansson S, Nagy P, García Rodríguez LA. Risk of seizure associated with use of acid-suppressive drugs: An observational cohort study. Epilepsy & Behavior 2016;62:72-80. [DOI: 10.1016/j.yebeh.2016.06.039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
25 Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol. 2013;6:443-451. [PMID: 23927671 DOI: 10.1586/17512433.2013.811206] [Cited by in Crossref: 68] [Cited by in F6Publishing: 56] [Article Influence: 8.5] [Reference Citation Analysis]
26 de Groot NL, van Haalen HG, Spiegel BM, Laine L, Lanas A, Focks JJ, Siersema PD, van Oijen MG. Gastroprotection in low-dose aspirin users for primary and secondary prevention of ACS: results of a cost-effectiveness analysis including compliance. Cardiovasc Drugs Ther 2013;27:341-57. [PMID: 23417566 DOI: 10.1007/s10557-013-6448-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
27 Peng YC, Lin CL, Yeh HZ, Chang CS, Wu YL, Kao CH. Association Between the Use of Proton Pump Inhibitors and the Risk of ESRD in Renal Diseases: A Population-Based, Case-Control Study. Medicine (Baltimore). 2016;95:e3363. [PMID: 27082596 DOI: 10.1097/md.0000000000003363] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 4.2] [Reference Citation Analysis]
28 Jiménez-Avalos JA, Arrevillaga-Boni G, González-López L, García-Carvajal ZY, González-Avila M. Classical methods and perspectives for manipulating the human gut microbial ecosystem. Crit Rev Food Sci Nutr 2021;61:234-58. [PMID: 32114770 DOI: 10.1080/10408398.2020.1724075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
29 Dickman R, Maradey-Romero C, Gingold-Belfer R, Fass R. Unmet Needs in the Treatment of Gastroesophageal Reflux Disease. J Neurogastroenterol Motil 2015;21:309-19. [PMID: 26130628 DOI: 10.5056/jnm15105] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
30 Metaxas ES, Bain KT. Review of Proton Pump Inhibitor Overuse in the US Veteran Population. Journal of Pharmacy Technology 2015;31:167-76. [DOI: 10.1177/8755122515575177] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
31 Martí-Cabrera M, Martí-Masanet M, Esplugues JV. [Chronic use of proton pump inhibitors: is the risk of osteoporosis and fractures real?]. Gastroenterol Hepatol 2011;34:271-7. [PMID: 21419526 DOI: 10.1016/j.gastrohep.2011.01.002] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
32 Fass R. Alternative therapeutic approaches to chronic proton pump inhibitor treatment. Clin Gastroenterol Hepatol. 2012;10:338-345; quiz e39-40. [PMID: 22178462 DOI: 10.1016/j.cgh.2011.12.020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
33 Hermos JA, Young MM, Fonda JR, Gagnon DR, Fiore LD, Lawler EV. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed. Clin Infect Dis 2012;54:33-42. [PMID: 22100573 DOI: 10.1093/cid/cir767] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
34 Hwang IC, Chang J, Park SM. Association between proton pump inhibitor use and the risk of pancreatic cancer: A Korean nationwide cohort study. PLoS One 2018;13:e0203918. [PMID: 30208110 DOI: 10.1371/journal.pone.0203918] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
35 Hwang IC, Chang J, Park SM. Emerging hazard effects of proton pump inhibitor on the risk of colorectal cancer in low-risk populations: A Korean nationwide prospective cohort study. PLoS One 2017;12:e0189114. [PMID: 29216279 DOI: 10.1371/journal.pone.0189114] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
36 Fortinsky KJ, Bardou M, Barkun AN. Role of Medical Therapy for Nonvariceal Upper Gastrointestinal Bleeding. Gastrointest Endosc Clin N Am 2015;25:463-78. [PMID: 26142032 DOI: 10.1016/j.giec.2015.02.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
37 Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179. [PMID: 27825371 DOI: 10.1186/s12916-016-0718-z] [Cited by in Crossref: 148] [Cited by in F6Publishing: 123] [Article Influence: 24.7] [Reference Citation Analysis]
38 Rippel SW, Acra S, Correa H, Vaezi M, Di Lorenzo C, Walker LS. Pediatric patients with dyspepsia have chronic symptoms, anxiety, and lower quality of life as adolescents and adults. Gastroenterology 2012;142:754-61. [PMID: 22226783 DOI: 10.1053/j.gastro.2011.12.043] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
39 De Roo AC, Regenbogen SE. Clostridium difficile Infection: An Epidemiology Update. Clin Colon Rectal Surg 2020;33:49-57. [PMID: 32104156 DOI: 10.1055/s-0040-1701229] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
40 De Bruyne P, Ito S. Toxicity of long-term use of proton pump inhibitors in children. Arch Dis Child 2017;103:78-82. [DOI: 10.1136/archdischild-2017-314026] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 7.6] [Reference Citation Analysis]
41 Pritchard DM. Zollinger-Ellison syndrome: still a diagnostic challenge in the 21st century? Gastroenterology. 2011;140:1380-1383. [PMID: 21443889 DOI: 10.1053/j.gastro.2011.03.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
42 Kushner PR, Peura DA. Review of proton pump inhibitors for the initial treatment of heartburn: is there a dose ceiling effect? Adv Ther 2011;28:367-88. [PMID: 21484335 DOI: 10.1007/s12325-011-0013-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
43 Chan GC, Wong SH, Ng JK, Li PK, Szeto CC, Chow KM. Risk of peritonitis after gastroscopy in peritoneal dialysis patients. Perit Dial Int 2021;:8968608211018608. [PMID: 34032173 DOI: 10.1177/08968608211018608] [Reference Citation Analysis]
44 Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs 2012;72:437-45. [PMID: 22356286 DOI: 10.2165/11599320-000000000-00000] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
45 De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25(33): 4933-4944 [PMID: 31543684 DOI: 10.3748/wjg.v25.i33.4933] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
46 Wu J, Dickinson S, Elgebaly Z, Blogg S, Heaney A, Soo Y, Daniels B, Weekes L. Impact of NPS MedicineWise general practitioner education programs and Choosing Wisely Australia recommendations on prescribing of proton pump inhibitors in Australia. BMC Fam Pract 2020;21:85. [PMID: 32386520 DOI: 10.1186/s12875-020-01158-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Lapumnuaypol K, Thongprayoon C, Wijarnpreecha K, Tiu A, Cheungpasitporn W. Risk of fall in patients taking proton pump inhibitors: a meta-analysis. QJM: An International Journal of Medicine 2019;112:115-21. [DOI: 10.1093/qjmed/hcy245] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
48 Mannucci PM, Nobili A; REPOSI Investigators. Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Intern Emerg Med 2014;9:723-34. [DOI: 10.1007/s11739-014-1124-1] [Cited by in Crossref: 81] [Cited by in F6Publishing: 72] [Article Influence: 10.1] [Reference Citation Analysis]
49 Begley J, Smith T, Barnett K, Strike P, Azim A, Spake C, Richardson T. Proton pump inhibitor associated hypomagnasaemia - a cause for concern? Br J Clin Pharmacol 2016;81:753-8. [PMID: 26613375 DOI: 10.1111/bcp.12846] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
50 Le Bastard Q, Berthelot L, Soulillou JP, Montassier E. Impact of non-antibiotic drugs on the human intestinal microbiome. Expert Rev Mol Diagn 2021;:1-14. [PMID: 34225544 DOI: 10.1080/14737159.2021.1952075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Araujo e Silva AC, de Oliveira Lemos F, Gomes MT, Salas CE, Lopes MT. Role of gastric acid inhibition, prostaglandins and endogenous-free thiol groups on the gastroprotective effect of a proteolytic fraction from Vasconcellea cundinamarcensis latex. J Pharm Pharmacol 2015;67:133-41. [PMID: 25213103 DOI: 10.1111/jphp.12318] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
52 Peng YC, Lin CL, Hsu WY, Chow WK, Lee SW, Yeh HZ, Chen CC, Kao CH. Association Between Cholangiocarcinoma and Proton Pump Inhibitors Use: A Nested Case-Control Study. Front Pharmacol 2018;9:718. [PMID: 30018559 DOI: 10.3389/fphar.2018.00718] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
53 Fohl AL, Regal RE. Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all? World J Gastrointest Pharmacol Ther 2011; 2(3): 17-26 [PMID: 21731913 DOI: 10.4292/wjgpt.v2.i3.17] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
54 Joo MK, Park JJ, Chun HJ. Proton pump inhibitor: The dual role in gastric cancer. World J Gastroenterol 2019; 25(17): 2058-2070 [PMID: 31114133 DOI: 10.3748/wjg.v25.i17.2058] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
55 Mermelstein J, Mermelstein AC, Chait MM. Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole. Clin Exp Gastroenterol 2016;9:163-72. [PMID: 27471402 DOI: 10.2147/CEG.S91602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
56 Lin YT, Lin TY, Hung SC, Liu PY, Wu PH, Chuang YS, Hung WC, Chiu YW, Kuo MC, Wu CY. Anti-Acid Drug Treatment Induces Changes in the Gut Microbiome Composition of Hemodialysis Patients. Microorganisms 2021;9:286. [PMID: 33573326 DOI: 10.3390/microorganisms9020286] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Huerta-Iga FM, Tamayo-de la Cuesta JL, Noble-Lugo A, Remes-Troche JM, Valdovinos-Díaz MA, Carmona-Sánchez RI; el Grupo Mexicano para el Estudio de la Enfermedad por Reflujo Gastroesofágico 2011. [The Mexican consensus on gastroesophageal reflux disease. Part I]. Rev Gastroenterol Mex 2012;77:193-213. [PMID: 23153413 DOI: 10.1016/j.rgmx.2012.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
58 Pasina L, Zanotta D, Puricelli S, Djignefa DC, Bonoldi G. Proton pump inhibitors and risk of hypomagnesemia. European Journal of Internal Medicine 2015;26:e25-6. [DOI: 10.1016/j.ejim.2015.06.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
59 Kim TJ, Kim ER, Hong SN, Kim YH, Lee YC, Kim HS, Kim K, Chang DK. Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users. Sci Rep 2019;9:11696. [PMID: 31406189 DOI: 10.1038/s41598-019-48173-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
60 Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med. 2014;34:771-785. [PMID: 25439276 DOI: 10.1016/j.cll.2014.08.008] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 9.0] [Reference Citation Analysis]
61 Ruiz-Irastorza G, Espinosa G, Frutos MA, Jiménez Alonso J, Praga M, Pallarés L, Rivera F, Robles Marhuenda Á, Segarra A, Quereda C; Grupo de Enfermedades Autoinmunes Sistémicas de la Sociedad Española de Medicina Interna., Sociedad Española de Nefrología. [Diagnosis and treatment of lupus nephritis]. Rev Clin Esp 2012;212:147.e1-30. [PMID: 22361331 DOI: 10.1016/j.rce.2012.01.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Freedberg DE, Haynes K, Denburg MR, Zemel BS, Leonard MB, Abrams JA, Yang YX. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. Osteoporos Int. 2015;26:2501-2507. [PMID: 25986385 DOI: 10.1007/s00198-015-3168-0] [Cited by in Crossref: 60] [Cited by in F6Publishing: 46] [Article Influence: 8.6] [Reference Citation Analysis]
63 Roulet L, Vernaz N, Giostra E, Gasche Y, Desmeules J. [Adverse effects of proton pump inhibitors: should we worry about long-term exposure?]. Rev Med Interne 2012;33:439-45. [PMID: 22284952 DOI: 10.1016/j.revmed.2011.12.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
64 Park JH, Lee J, Yu SY, Jung JH, Han K, Kim DH, Rhee J. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease. BMC Geriatr 2020;20:407. [PMID: 33059626 DOI: 10.1186/s12877-020-01794-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
65 Schirmer CM, Kornbluth J, Heilman CB, Bhardwaj A. Gastrointestinal prophylaxis in neurocritical care. Neurocrit Care. 2012;16:184-193. [PMID: 21748505 DOI: 10.1007/s12028-011-9580-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
66 Park S, Hyun YJ, Kim YR, Lee JH, Ryu S, Kim JM, Oh WY, Na HS, Lee JG, Seo DW, Hwang IY, Park Z, Jang IJ, Oh J, Choi SE. Effects of CYP2C19 Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers. J Korean Med Sci 2017;32:729-36. [PMID: 28378544 DOI: 10.3346/jkms.2017.32.5.729] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
67 Yang S, Rider BB, Baehr A, Ducoffe AR, Hu DJ. Racial and ethnic disparities in health care-associated Clostridium difficile infections in the United States: State of the science. Am J Infect Control 2016;44:91-6. [PMID: 26454749 DOI: 10.1016/j.ajic.2015.08.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
68 Kim M, Dam A, Green J. Common GI Drug Interactions in the Elderly. Curr Treat Options Gastroenterol 2014;12:292-309. [PMID: 25031070 DOI: 10.1007/s11938-014-0024-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
69 Patel A, Amaechi BT, Brady C. Prevention and Control of Dental Erosion: Gastroesophageal Reflux Disease Management. In: Amaechi BT, editor. Dental Erosion and Its Clinical Management. Cham: Springer International Publishing; 2015. pp. 203-24. [DOI: 10.1007/978-3-319-13993-7_12] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
70 Sugano K, Kontani T, Katsuo S, Takei Y, Sakaki N, Ashida K, Mizokami Y, Asaka M, Matsui S, Kanto T. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol. 2012;47:540-552. [PMID: 22388884 DOI: 10.1007/s00535-012-0541-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
71 Helgadóttir H, Lund SH, Gizurarson S, Waldum H, Björnsson ES. Pharmacokinetics of single and repeated oral doses of esomeprazole and gastrin elevation in healthy males and females. Scand J Gastroenterol 2021;56:128-36. [PMID: 33327801 DOI: 10.1080/00365521.2020.1859610] [Reference Citation Analysis]
72 Zalvan CH, Hu S, Greenberg B, Geliebter J. A Comparison of Alkaline Water and Mediterranean Diet vs Proton Pump Inhibition for Treatment of Laryngopharyngeal Reflux. JAMA Otolaryngol Head Neck Surg. 2017;143:1023-1029. [PMID: 28880991 DOI: 10.1001/jamaoto.2017.1454] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]
73 Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev 2017;11:CD011194. [PMID: 29161458 DOI: 10.1002/14651858.CD011194.pub3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
74 Ito T, Igarashi H, Jensen RT. Zollinger-Ellison syndrome: Recent advances and controversies. Curr Opin Gastroenterol. 2013;29:650-661. [PMID: 24100728 DOI: 10.1097/mog.0b013e328365efb1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
75 Peterson C. A case study of chiropractic management of pregnancy-related heartburn with postulated fetal epigenome implications. Explore (NY) 2012;8:304-8. [PMID: 22938750 DOI: 10.1016/j.explore.2012.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
76 Salvo EM, Ferko NC, Cash SB, Gonzalez A, Kahrilas PJ. Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors. Aliment Pharmacol Ther 2021;54:129-43. [PMID: 34114655 DOI: 10.1111/apt.16407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
77 Song KH, Lee YC, Fan D, Ge Z, Ji F, Chen M, Jung HC, Bo J, Lee SW, Kim J. Healing Effects of Rebamipide and Omeprazole in Helicobacter pylori-Positive Gastric Ulcer Patients after Eradication Therapy: A Randomized Double-Blind, Multinational, Multi-Institutional Comparative Study. Digestion 2011;84:221-9. [DOI: 10.1159/000329353] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
78 Freedberg DE, Salmasian H, Friedman C, Abrams JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol 2013;108:1794-801. [PMID: 24060760 DOI: 10.1038/ajg.2013.333] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 8.0] [Reference Citation Analysis]
79 Hershcovici T, Fass R. Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy. Drugs. 2011;71:2381-2389. [PMID: 22117130 DOI: 10.2165/11597300-000000000-00000] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
80 Fiocca R, Mastracci L, Attwood SE, Ell C, Galmiche JP, Hatlebakk J, Bärthel A, Långström G, Lind T, Lundell L; LOTUS trial collaborators. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Aliment Pharmacol Ther 2012;36:959-71. [PMID: 22998687 DOI: 10.1111/apt.12052] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
81 Pasina L, Urru SAM, Mandelli S, Giua C, Minghetti P; SGCP Investigators. Evidence-based and unlicensed indications for proton pump inhibitors and patients’ preferences for discontinuation: a pilot study in a sample of Italian community pharmacies. J Clin Pharm Ther 2016;41:220-3. [DOI: 10.1111/jcpt.12371] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
82 Glicksman JT, Mick PT, Fung K, Carroll TL. Prokinetic agents and laryngopharyngeal reflux disease: Prokinetic agents and laryngopharyngeal reflux disease: a systematic review. Laryngoscope. 2014;124:2375-2379. [PMID: 24782414 DOI: 10.1002/lary.24738] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
83 Safe M, Chan WH, Leach ST, Sutton L, Lui K, Krishnan U. Widespread use of gastric acid inhibitors in infants: Are they needed? Are they safe? World J Gastrointest Pharmacol Ther 2016; 7(4): 531-539 [PMID: 27867686 DOI: 10.4292/wjgpt.v7.i4.531] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
84 Hammond N, Wang Y, Dimachkie MM, Barohn RJ. Nutritional neuropathies. Neurol Clin. 2013;31:477-489. [PMID: 23642720 DOI: 10.1016/j.ncl.2013.02.002] [Cited by in Crossref: 54] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
85 Fako VE, Wu X, Pflug B, Liu JY, Zhang JT. Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase. J Med Chem 2015;58:778-84. [PMID: 25513712 DOI: 10.1021/jm501543u] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
86 Cea Soriano L, Ruigómez A, Johansson S, García Rodríguez LA. Study of the Association Between Hip Fracture and Acid-Suppressive Drug Use in a UK Primary Care Setting. Pharmacotherapy 2014;34:570-81. [DOI: 10.1002/phar.1410] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
87 Maléth J, Hegyi P. Long-term proton pump inhibitor therapy and osteoporosis. Is there a real danger? Orvosi Hetilap 2013;154:1005-9. [DOI: 10.1556/oh.2013.29656] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
88 Cea-Soriano L, Johansson S, García Rodríguez LA. Risk factors for falls with use of acid-suppressive drugs. Epidemiology 2013;24:600-7. [PMID: 23676267 DOI: 10.1097/EDE.0b013e318294bec6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
89 Meli M, Raffa MP, Malta R, Morreale I, Aprea L, D’alessandro N. The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients. Int J Clin Pharm 2015;37:1152-61. [DOI: 10.1007/s11096-015-0178-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
90 Takabayashi N, Murata K, Tanaka S, Kawakami K. Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke. PharmacoEconomics 2015;33:1091-100. [DOI: 10.1007/s40273-015-0289-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Huang X, Sun X, Yu X, Qian H. Efficacy and safety of Sijunzi Decoction for peptic ulcers: A systematic review and meta-analysis. Journal of Traditional Chinese Medical Sciences 2018;5:237-54. [DOI: 10.1016/j.jtcms.2018.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 Tamura T, Sakaeda T, Kadoyama K, Okuno Y. Omeprazole- and esomeprazole-associated hypomagnesaemia: data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2012;9:322-326. [PMID: 22745572 DOI: 10.7150/ijms.4397] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
93 Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol 2012;28:615-20. [PMID: 23010681 DOI: 10.1097/MOG.0b013e328358d5b9] [Cited by in Crossref: 85] [Cited by in F6Publishing: 36] [Article Influence: 9.4] [Reference Citation Analysis]
94 Lee KN, Lee OY, Choi MG, Choi SR, Lee DH, Lee YC, Kim TN, Choi SC, Rew JS, Seol SY. Prevention of NSAID-associated gastroduodenal injury in healthy volunteers-a randomized, double-blind, multicenter study comparing DA-9601 with misoprostol. J Korean Med Sci 2011;26:1074-80. [PMID: 21860559 DOI: 10.3346/jkms.2011.26.8.1074] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
95 Johnson DA, Oldfield EC. Reported Side Effects and Complications of Long-term Proton Pump Inhibitor Use: Dissecting the Evidence. Clinical Gastroenterology and Hepatology 2013;11:458-64. [DOI: 10.1016/j.cgh.2012.11.031] [Cited by in Crossref: 65] [Cited by in F6Publishing: 50] [Article Influence: 7.2] [Reference Citation Analysis]
96 Weinstein DH, deRijke S, Chow CC, Foruraghi L, Zhao X, Wright EC, Whatley M, Maass-Moreno R, Chen CC, Wank SA. A new method for determining gastric acid output using a wireless pH-sensing capsule. Aliment Pharmacol Ther. 2013;37:1198-1209. [PMID: 23639004 DOI: 10.1111/apt.12325] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
97 El-kimary EI, Ragab MAA. Recent Analytical Methodologies for the Determination of Omeprazole and/or Its Active Isomer Esomeprazole in Different Matrices: A Critical Review. Critical Reviews in Analytical Chemistry. [DOI: 10.1080/10408347.2020.1791042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Slaughter JL, Stenger MR, Reagan PB, Jadcherla SR. Neonatal Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Treatment at United States Children's Hospitals. J Pediatr 2016;174:63-70.e3. [PMID: 27131401 DOI: 10.1016/j.jpeds.2016.03.059] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
99 Zheng M, Luan S, Gao S, Cheng L, Hao B, Li J, Chen Y, Hou X, Chen L, Li H. Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein kinase. Oncotarget 2017;8:39143-53. [PMID: 28388576 DOI: 10.18632/oncotarget.16609] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
100 Hagymási K, Müllner K, Herszényi L, Tulassay Z. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2011;12:873-888. [PMID: 21692617 DOI: 10.2217/pgs.11.4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]
101 Peng Y, Huang L, Lin C, Hsu W, Chang C, Yeh H, Kao C. Association between proton pump inhibitors use and risk of gastric cancer in patients with GERD. Gut 2019;68:374-6. [DOI: 10.1136/gutjnl-2018-316057] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
102 Dovjak P. [Duodenal ulcers, gastric ulcers and Helicobacter pylori]. Z Gerontol Geriatr 2017;50:159-69. [PMID: 28150170 DOI: 10.1007/s00391-017-1190-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
103 Kuo CJ, Lin CY, Chen CW, Hsu CY, Hsieh SY, Chiu CT, Lin WR. Risk of Enteric Infection in Patients with Gastric Acid Supressive Drugs: A Population-Based Case-Control Study. J Pers Med 2021;11:1063. [PMID: 34834415 DOI: 10.3390/jpm11111063] [Reference Citation Analysis]
104 Rodríguez L, Rodríguez P, Neto MG, Ayala JC, Saba J, Berel D, Conklin J, Soffer E. Short-term electrical stimulation of the lower esophageal sphincter increases sphincter pressure in patients with gastroesophageal reflux disease. Neurogastroenterol Motil. 2012;24:446-450, e213. [PMID: 22292889 DOI: 10.1111/j.1365-2982.2012.01878.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
105 Rababa M, Rababa'h A. The inappropriate use of proton pump inhibitors and its associated factors among community-dwelling older adults. Heliyon 2021;7:e07595. [PMID: 34337188 DOI: 10.1016/j.heliyon.2021.e07595] [Reference Citation Analysis]
106 Nyandege AN, Slattum PW, Harpe SE. Risk of Fracture and the Concomitant Use of Bisphosphonates With Osteoporosis-Inducing Medications. Ann Pharmacother 2015;49:437-47. [DOI: 10.1177/1060028015569594] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
107 Gill JM, Player MS, Metz DC. Balancing the risks and benefits of proton pump inhibitors. Ann Fam Med 2011;9:200-2. [PMID: 21555747 DOI: 10.1370/afm.1269] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
108 Ha VH, Ngo M, Chu MP, Ghosh S, Sawyer MB, Chambers CR. Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer? J Oncol Pharm Pract 2015;21:194-200. [DOI: 10.1177/1078155214527145] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
109 Scheurlen M. Langzeitbehandlung mit Protonenpumpenhemmern: Wer braucht die Prophylaxe tatsächlich? Internist 2013;54:366-72. [DOI: 10.1007/s00108-012-3231-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
110 Gwee KA, Goh V, Lima G, Setia S. Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: Risks versus benefits. J Pain Res. 2018;11:361-374. [PMID: 29491719 DOI: 10.2147/jpr.s156938] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
111 Le Bastard Q, Al-Ghalith GA, Grégoire M, Chapelet G, Javaudin F, Dailly E, Batard E, Knights D, Montassier E. Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications. Aliment Pharmacol Ther 2018;47:332-45. [PMID: 29205415 DOI: 10.1111/apt.14451] [Cited by in Crossref: 94] [Cited by in F6Publishing: 86] [Article Influence: 18.8] [Reference Citation Analysis]
112 Heading RC. Proton pump inhibitor failure in gastro-oesophageal reflux disease: a perspective aided by the Gartner hype cycle. Clin Med (Lond) 2017;17:132-6. [PMID: 28365622 DOI: 10.7861/clinmedicine.17-2-132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
113 Koestler BJ, Waters CM. Intestinal GPS: bile and bicarbonate control cyclic di-GMP to provide Vibrio cholerae spatial cues within the small intestine. Gut Microbes 2014;5:775-80. [PMID: 25621620 DOI: 10.4161/19490976.2014.985989] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
114 Wang JC, Sung FC, Men M, Wang KA, Lin CL, Kao CH. Bidirectional association between fibromyalgia and gastroesophageal reflux disease: two population-based retrospective cohort analysis. Pain 2017;158:1971-8. [PMID: 28683023 DOI: 10.1097/j.pain.0000000000000994] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
115 Pinto-Sanchez MI, Yuan Y, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev 2017;3:CD011194. [PMID: 28271513 DOI: 10.1002/14651858.CD011194.pub2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
116 Lucas CJ, Martin JH. Pharmacokinetic-Guided Dosing of New Oral Cancer Agents. The Journal of Clinical Pharmacology 2017;57:S78-98. [DOI: 10.1002/jcph.937] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
117 von Rahden BH, Scheurlen M, Filser J, Stein HJ, Germer CT. [Newly recognized side-effects of proton pump inhibitors. Arguments in favour of fundoplication for GERD?]. Chirurg. 2012;83:38-44. [PMID: 21909830 DOI: 10.1007/s00104-011-2173-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
118 Kim JM, Kim SH, Ko SH, Jung J, Chun J, Kim N, Jung HC, Kim JS. The guggulsterone derivative GG-52 inhibits NF-κB signaling in gastric epithelial cells and ameliorates ethanol-induced gastric mucosal lesions in mice. American Journal of Physiology-Gastrointestinal and Liver Physiology 2013;304:G193-202. [DOI: 10.1152/ajpgi.00103.2012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
119 Avendaño-Reyes JM, Jaramillo-Ramírez H. [Prophylaxis for stress ulcer bleeding in the intensive care unit]. Rev Gastroenterol Mex 2014;79:50-5. [PMID: 24629722 DOI: 10.1016/j.rgmx.2013.05.004] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
120 Heidelbaugh JJ, Metz DC, Yang YX. Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? Int J Clin Pract. 2012;66:582-591. [PMID: 22607510 DOI: 10.1111/j.1742-1241.2012.02921.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
121 Almario CV, Metz DC, Haynes K, Yang YX. Risk of community-acquired pneumonia in patients with a diagnosis of pernicious anemia: a population-based retrospective cohort study. Eur J Gastroenterol Hepatol 2015;27:1259-64. [PMID: 26225868 DOI: 10.1097/MEG.0000000000000444] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
122 Luk CP, Parsons R, Lee YP, Hughes JD. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother. 2013;47:773-780. [PMID: 23632281 DOI: 10.1345/aph.1r556] [Cited by in Crossref: 45] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
123 Hershcovici T, Fass R. Pharmacological management of GERD: where does it stand now? Trends Pharmacol Sci. 2011;32:258-264. [PMID: 21429600 DOI: 10.1016/j.tips.2011.02.007] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
124 Gramont B, Bertoletti L, Roy M, Roblin X, Tardy B, Cathébras P. [Use and management of proton pump inhibitors: An observational study]. Therapie 2020;75:649-62. [PMID: 32591130 DOI: 10.1016/j.therap.2020.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
125 Schiff M, Peura D. HZT-501 (DUEXIS(®); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Expert Rev Gastroenterol Hepatol 2012;6:25-35. [PMID: 22149579 DOI: 10.1586/egh.11.88] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
126 Gau JT, Yang YX, Chen R, Kao TC. Uses of proton pump inhibitors and hypomagnesemia. Pharmacoepidemiol Drug Saf. 2012;21:553-559. [PMID: 22337212 DOI: 10.1002/pds.3224] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]